Subex Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

4
Nisha Dutt (MD & CEO), Sumit Agarwal (CFO), Harsha Angeri (Head Corporate Strategy & AI), Ramu Akkili (Company Secretary & Compliance Officer)

Analysts

11
Abhishek Kale, Ajay Desai, Harshit Singhania, Jitendra Bhutoria, Kiran Chheda, Mahesh Kumar, Meet Mehta, Nanda Gopal, Nishita Shanklesha, Patrick Matthias, Sanjyot Khare

Financials & KPIs

Geographic & Segment Commentary

• Partner Ecosystem Management (PAM): Secured renewal with a tier-1 operator in Asia Pacific; PAM has received renewed investment in team and product roadmap over past few years, and is now seeing stronger deal flow. Management positions PAM as the third equally important growth pillar alongside Revenue Assurance and Fraud Management (RAFM).

• Middle East: Renewed managed services and software license agreement with a tier-1 operator despite geopolitical tensions. Delivery fully offshored to Bangalore (from Dubai, Kuwait, Qatar on-site resources); contracts are taking longer to close due to legal Ts & Cs and cautious buyer behavior, though no cancellations reported—delays are one to two months, not quarters.

• Europe & US: Secured new business assurance and fraud management business with a leading operator in Europe; US described as "better" and Europe as "okay." These wins, combined with the APAC PAM renewal, demonstrate portfolio traction across geographies.

• Asia Pacific & Africa: APAC experiencing extended decision timelines in some deals; Africa remains inherently slow to close contracts—both regions showing caution but no deal losses.

Company-Specific & Strategic Commentary

• Capital Restructuring: Board is actively considering writing off accumulated losses against equity capital following shareholder suggestion. Will appoint a consultant to determine optimal structure; process will require board approval, shareholder approval, and NCLT clearance—expected to be a long-drawn process but strongly under consideration.

• ESOP Scheme: Received board approval for 5% ESOP; will go to postal ballot within ~2 weeks. Market acquisition capped at 2% per financial year; expects execution around Q3 FY27 (may extend to full year depending on company convenience). Award allocations must be completed within 6 months of acquisition.

• R&D Investment & GenAI: R&D intensity to increase in coming quarters; investments span three horizons—H1 (current product GenAI enablement), H2 (portfolio expansion into new fraud types like account takeover and social engineering), H3 (highly experimental bets in data centers and satellite telecom; ~10% of spend). Aspiration is to transition revenue split to 60-30-10 across horizons over next two years.

• Investor Engagement: Completed first non-deal roadshow (NDR) in three years with EY; investor questions have shifted from turnaround viability to growth sustainability and capital allocation. Plans to run quarterly NDRs across Mumbai, Ahmedabad, Chennai rather than a single annual Investor Day; resumed post-silent period.

• FraudZap: Managing director confirmed "we have already recovered our investment on this" with margins "much higher" than other products; one new customer signing delayed by ~a month from Q1 to Q2, part of the broader legal negotiation slowdown.

• Litigation & Recoveries: Sectorial contract litigation ongoing in Middle East jurisdiction; one of three entities already settled and dispensed with, second expected to close this quarter, third fully under litigation with expectation to resolve within the financial year.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Capital Restructuring & Equity Reduction

• Question: Has the board considered reducing equity capital by writing off pending losses to make the company leaner? (Kiran Chheda)
• Answer: The suggestion was raised at the board meeting concluding yesterday; management is acutely aware structural balance sheet changes are needed once numbers look good. Will appoint a consultant to determine best approach protecting all shareholder interests; process will require board approval, shareholder approval, and NCLT clearance—long-drawn but strongly under consideration. (Nisha Dutt)

CEO Incentives & ESOP

• Question: Has the board considered rewarding management better given performance? And when will the ESOP be executed, at what price? (Kiran Chheda, Ajay Desai)
• Answer: Board is discussing meaningfully improving stake for core people, with action expected within weeks. ESOP: 5% approved by board; postal ballot within ~2 weeks; acquisition limited to 2% per financial year; share price based on 60-day trading average; expected execution around Q3 FY27, awards must be allocated within 6 months of acquisition. (Nisha Dutt, Kiran Chheda)

Pipeline & Order Visibility

• Question: What is the executable order pipeline size and total pending order wins? (Patrick Matthias)
• Answer: Management cannot disclose specific numbers due to competitive sensitivity—Subex is the only listed player among top-4 competitors, all private. Qualified pipeline is maintained at 3-4x annual order intake target; 70% of revenue is recurring (backlog), 30% from new wins converting partially in-year. Deals announced last FY totaled ~$18-20 million; 30-40% of that value will convert to revenue this year. Management declined to give directional guidance on an earnings call, pointing to industry-relevant growth expectations versus 50% aspiration. (Nisha Dutt)

Margin Sustainability

• Question: Where do EBITDA margins stabilize? Is the current level sustainable? (Harshit Singhania, Mahesh Kumar)
• Answer: Margins should remain "in this ballpark" (around 21%); there is a threshold below which contracts aren't accepted, varying by geography. Management will not pursue indefinite margin expansion—investment into AI, GenAI product enhancement, and R&D takes priority. Expect "reasonable margin expansion" from FY26 exit levels, then reinvestment of excess. (Nisha Dutt)

Order Closure Delays & Geopolitical Impact

• Question: Are order closures delayed? What's happening in US/Europe? (Sanjyot Khare)
• Answer: Middle East is showing slowdown—not cancellations—with contracts taking longer due to legal Ts & Cs negotiation (LOLs). Some Q1 closures shifted by ~a month, not a quarter; nothing lost. US better, Europe okay, APAC taking longer timelines, Africa inherently slow. Legal watertightness prioritized over closing July 31st. Expect announcements in coming quarters. (Nisha Dutt)

Contract-to-Subscription Window

• Question: What's the window from contract signing to subscription revenue, and work done to shorten it? (Abhishek Kale)
• Answer: Typically 4-5 quarters from signing to subscription revenue, varying by product and implementation complexity; milestone-based revenue (BRD/FSD sign-offs) recognized during implementation. Goal is to compress by one quarter; achieved 45 days gain on a recent project (average 1-1.5 months). Internal initiatives focus on libraries, reusability to crash timeline. (Nisha Dutt)

FraudZap Margins & Customers

• Question: Any new FraudZap customers this quarter and are margins comfortable? (Abhishek Kale)
• Answer: One FraudZap deal slipped from Q1 to Q2 (part of the legal delay); investment already recovered, margins "much higher" than other products. Management has clarity on where FraudZap margins land after several contracts. (Nisha Dutt)

R&D Investment & Middle East Working Capital

• Question: Where is R&D spend increasing, and how is Middle East being managed? (Meet Mehta)
• Answer: R&D intensity will absolutely increase—two buckets: engineering and AI engineering. Three-horizon framework: H1 (current product GenAI enablement), H2 (portfolio expansion to new fraud types: ATO, social engineering), H3 (highly experimental bets ~10% of spend: satellites, data centers). People expense will be replaced by token expense. Middle East: all delivery offshored to Bangalore; slowdown baked into AOP; no further capital infusion expected for Middle East subsidiary (self-sufficient). (Nisha Dutt, Sumit Agarwal)

Sectorial Contract Litigation & Investment Markup

• Question: Any recoveries from written-off sectorial contracts, and how is the IDcentral divestment investment performing? (Jitendra Bhutoria)
• Answer: Litigation ongoing in Middle East jurisdiction; one of three entities settled and dispensed with; second expected to close this quarter; third fully under litigation, targeted to close within FY27. The unlisted investment from IDcentral divestment is performing very well; FMV revaluation markup expected in Q2 pending evaluation. (Nisha Dutt, Sumit Agarwal)

Vision & Long-Term Strategy

• Question: What is the end-state vision beyond Horizons 1-3? (Nanda Gopal)
• Answer: Aspiration is to migrate revenue split toward 60-30-10 across H1-H2-H3. Target areas: GenAI-enabled current portfolio (RA, FM, PAM), entering adjacent markets riding large CapEx waves (data centers, satellites), and expanding fraud portfolio to combat complex new fraud types. Avoid utilities—not where excitement is. Management took feedback to articulate vision better next quarter. (Nisha Dutt)

Key Takeaway

Subex delivered a strong Q1 FY27 with revenue of ₹79.45 crores (+19.7% YoY, +8.9% QoQ), EBITDA of ₹16.87 crores (21.2% margin, fourfold YoY growth), and normalized PAT of ₹16.91 crores—results management attributes to multi-year foundation building (operational discipline, backlog execution, cost control) rather than one-off events. The strategic narrative now centers on accelerating growth: PAM is emerging as a third product pillar alongside RAFM with renewals across Middle East, Europe, and APAC; the company is positioning for GenAI-era product competitiveness through increased R&D intensity across three investment horizons targeting existing products, new fraud types, and future-facing bets in data centers and satellites. Management has line of sight to ₹100 crores quarterly revenue within a few quarters, guided margins to remain in the ~21% ballpark with reinvestment rather than indefinite expansion, and launched an ESOP (2% acquisition expected by Q3) plus capital restructuring study to write off accumulated losses. Key watch points: Middle East slowdown shifting contract closures by 1-2 months (no cancellations), litigation on two of three sectorial contracts targeted for closure within FY27, and balance sheet optionality from ₹184.8 crores cash for potential inorganic moves or FMV markups on investments.